Similar articles

• Vaccination as a measure for prevention of neonatal GBS infection.

  Baker CJ, Kasper DL. Baker CJ, et al. Antibiot Chemother (1971). 1985;35:281-90. doi: 10.1159/000410381. Antibiot Chemother (1971). 1985. PMID: 3901904 No abstract available.
• Conjugate vaccines against group B Streptococcus types IV and VII.

  Paoletti LC, Kasper DL. Paoletti LC, et al. J Infect Dis. 2002 Jul 1;186(1):123-6. doi: 10.1086/341073. Epub 2002 Jun 14. J Infect Dis. 2002. PMID: 12089673
• Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.

  Wessels MR, Paoletti LC, Pinel J, Kasper DL. Wessels MR, et al. J Infect Dis. 1995 Apr;171(4):879-84. doi: 10.1093/infdis/171.4.879. J Infect Dis. 1995. PMID: 7706814
• Group B Streptococcus: global incidence and vaccine development.

  Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, Grandi G, Rappuoli R. Johri AK, et al. Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6. Nat Rev Microbiol. 2006. PMID: 17088932 Free PMC article. Review.
• Vaccine prevention of group B streptococcal disease.

  Baker CJ. Baker CJ. Pediatr Ann. 1993 Dec;22(12):711-4. doi: 10.3928/0090-4481-19931201-05. Pediatr Ann. 1993. PMID: 8139871 Review. No abstract available.